Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (5)
  • Open Access


    A novel prognostic gene signature, nomogram and immune landscape based on tanshinone IIA drug targets for hepatocellular carcinoma: Comprehensive bioinformatics analysis and in vitro experiments


    BIOCELL, Vol.47, No.7, pp. 1519-1535, 2023, DOI:10.32604/biocell.2023.027026

    Abstract Background: Tanshinone IIA, one of the main ingredients of Danshen, is used to treat hepatocellular carcinoma (HCC). However, potential targets of the molecule in the therapy of HCC are unknown. Methods: In this study, we collected the tanshinone IIA targets from public databases for investigation. We screened differentially expressed genes (DEGs) across HCC and normal tissues using mRNA expression profiles from The Cancer Genome Atlas (TCGA). Univariate Cox regression analysis and least absolute shrinkage and selection operator (LASSO) Cox regression models were used to identify and construct the prognostic gene signature. Results: Finally, we discovered common… More >

  • Open Access


    Transcriptional factor RUNX1: A potential therapeutic target for fibrotic pulmonary disease


    BIOCELL, Vol.47, No.4, pp. 697-705, 2023, DOI:10.32604/biocell.2023.026148

    Abstract Runt-related transcription factor-1 (RUNX1), also known as the core-binding factor alpha 2 subunit, is closely related to human leukemia. The functions of RUNX1 in modulating cell proliferation, differentiation, and survival in multiple systems have been gradually discovered with the emergence of transgenic mice. RUNX1 is a powerful transcription factor implicated in diverse signaling pathways and cellular mechanisms that participate in lung development and pulmonary diseases. RUNX1 has recently been identified as a target regulator of fibrotic remodeling diseases, particularly in the kidney. However, the role of RUNX1 in pulmonary fibrosis is unclear. Pulmonary fibrosis is More >

  • Open Access


    Utilization of kinase inhibitors as novel therapeutic drug targets: A review


    Oncology Research, Vol.30, No.5, pp. 221-230, 2022, DOI:10.32604/or.2022.027549

    Abstract Kinase inhibitors are a significant and continuously developing division of target therapeutics. The drug discovery and improvement efforts have examined numerous attempts to target the signaling pathway of kinases. The Kinase inhibitors have been heralded as a game-changer in cancer treatment. For developing kinase inhibitors as a treatment for various non-malignant disorders like auto-immune diseases, is currently undergoing extensive research. It may be beneficial to investigate whether cell-specific kinase inhibitor administration enhances therapeutic efficacy and decreases adverse effects. The goal of the current review is to gain insight into the role of kinase inhibitors in… More >

  • Open Access


    Applications of CRISPR-Cas System in Tumor Biology

    Mengdan Ma1,2, Yuchen Liu1,*, Weiren Huang1,*

    Oncologie, Vol.23, No.4, pp. 463-492, 2021, DOI:10.32604/oncologie.2022.019415

    Abstract The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system, which is an RNA-guided nuclease system, plays an important role in the adaptive immune response of bacteria, and it is a rapidly developing gene editing technology. It has been widely used in a variety of cells, microorganisms, plants, and animals. This technique has helped to overcome the limitations of previous gene editing methods, and it has promoted the development of synthetic biology, genetics, and proteomics. The ability of the CRISPR-Cas system to modify the genetic components of a system has led to various practical applications, such… More >

  • Open Access


    in silico Method for the Identification of Mycobacterial sp. Potential Drug Targets

    Ashutosh Singh1, Shruti Mishra2, Dhwani Raghav1, Asheesh shanker1, Vinay Sharma1

    The International Conference on Computational & Experimental Engineering and Sciences, Vol.6, No.2, pp. 119-124, 2008, DOI:10.3970/icces.2008.006.119

    Abstract Drug resistance has increased the pace of war against the ever-growing challenge of mycobacterial infections particularly with the growing menace of tuberculosis (TB).Previous studies reported several essential and virulent genes of mycobacterium like virS gene and mymA operon[1] through experimental approaches. However, Post genomic approach applied for the identification of targets for tuberculosis which includes the comparison of Mycobacterium tuberculosis CDC1551 proteome against database of essential genes and proteome of Homo sapiens. A total of approx 4000 proteins were studied and compared and 19 proteins were found to possess potentiality to call as Targets. More >

Displaying 1-10 on page 1 of 5. Per Page